 "Biocon gains on approval for insulin Glargine in Mexico")
Shares of Biocon were trading higher by 3% at Rs 481 on the National Stock Exchange (NSE) in early morning trade after the biopharmaceuticals major said it has received approval for its Insulin Glargine by Cofepris, the Mexican health authority, through its partner PiSA Farmaceutica.
Insulin Glargine will augment the affordable insulins therapy for diabetes management. Galactus by PiSA is the first Insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012, Biocon said in a release.
The stock opened at Rs 481 and touched a high of Rs 483 on the NSE so far. A combined 331,033 shares changed hands on the counter till 0927 hours on the NSE and BSE.
Insulin Glargine will augment the affordable insulins therapy for diabetes management. Galactus by PiSA is the first Insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012, Biocon said in a release.
The stock opened at Rs 481 and touched a high of Rs 483 on the NSE so far. A combined 331,033 shares changed hands on the counter till 0927 hours on the NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%